ARCHIVES

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 9 | September 28, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Approves Rituxan For CLL

February 19, 2010

Herceptin Lowers Recurrence In Early Breast Cancer

November 25, 2005

Prostate Ultrasound Markers Concepts Approved by BSC

October 3, 1986

Survey Finds Misconceptions About Cancer Worldwide

August 29, 2008

Clinton Seeks Cut In NIH Increase

May 27, 1994

Book For Survivors, Other New Publications

August 23, 1991